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For the ongoing SARS-CoV-2 
pandemic, we hypothesise that the 
collected data will allow researchers 
and health-care professionals to 
better characterise the disease course 
and spectrum, quantitatively estimate 
associated risks, and identify specific 
risk factors that can be used to define 
screening strategies in pregnant 
women and adequate prevention 
meas ures, and to direct specific and 
early clinical management of women 
and fetuses at risk. In the spirit of 
open science and data sharing,10 the 
collected data will be available to 
any research group provided that 
they have a clear, non-redundant 
research question and biomedical 
research ethics committee approval. 
Any health-care provider supporting 
the registry by providing well docu-
mented cases will be considered as 
a collaborator of the registry in any 
future scientific publications.
We declare no competing interests.
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Center for Research and Innovation in Clinical 
Pharmaceutical Sciences, Institute of Pharmaceutical 
Sciences of Western Switzerland, Lausanne 
and clinicians involved in the care of 
pregnant patients during a pandemic, 
this situation feels like déjà vu, given 
the many similarities to the Zika virus 
epidemic only 5 years ago.3
To tweak resources, we have adjust-
ed the Zika virus international web 
registry9 to create COVI-Preg, a 
structured data collection tool available 
to any facility assessing pregnant 
patients for SARS-CoV-2 infection. 
Today, with increased mobility and 
considerable migration, we have to 
use the modern tool of worldwide 
and immediate communication to 
trigger knowledge sharing and prepare 
for rapid assessment of existing and 
future emergent pathogens. This 
registry and its associated international 
network will be organised to be rapidly 
adaptable to any other emerging 
infectious agent in the future. The 
feasibility of this global responsive 
and customisable structure for future 
emergent pathogens is supported by 
the strong platform of well established 
collaborations with 198 antenatal 
clinics from 23 countries in Africa, Asia, 
Europe, Oceania, and the Americas 
(figure). This structure will allow 
for the creation of a large dataset 
capturing global information in an 
attainable and realistic manner, with 
affordable costs and an acceptable 
timeframe.
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An international registry 
for emergent pathogens 
and pregnancy
Emerging infectious diseases 
require a global approach and 
adaptive tools to allow for rapid and 
comprehensive characterisation of 
the risks associated with the disease, 
particularly in pregnancy. Pregnant 
women are particularly vulnerable to 
infections because of their relative 
immunosuppressed state, restricted 
cardiorespiratory capacity, and the 
potential for adverse pregnancy or 
perinatal outcomes (eg, preterm 
birth, vertical transmission, fetal 
growth restriction, fetal anomalies, 
and death), as observed with severe 
acute respiratory syndrome-related 
coronavirus, Middle East respiratory 
syndrome-related coronavirus, 
malaria parasites, dengue virus, Zika 
virus, and chikungunya virus.1,2
Robust data acquisition on the 
effect of emergent pathogens on 
pregnancy is often absent, and often 
data are available after considerable 
delay,3 leaving scientists and clinicians 
seeking knowledge to depend 
solely on intuition, extrapolation, 
and case series as they emerge. The 
severe acute respiratory syndrome 
coronavirus 2 (SARS-Cov-2) pandemic 
is no exception.1,4–8 Large cohorts are 
required to allow for accurate risk 
estimates, and therefore a global 
perspective is needed. To scientists 
Figure: Network of antenatal clinics collaborating in the COVI-Preg registry, as of April 23, 2020
Each clinic location is represented by a red dot. 
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Group,5 but which Minerva and 
colleagues1 refuse to see.
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scheme in a high-income country 
(HIC) would make substantial 
savings by offering Alyson´s child 
a transplantation, because dialysis 
costs more than twice as much as 
kidney transplantation over the 
equivalent period.2,3 Alyson wants 
to donate her compatible kidney to 
her child. She could also be included 
in a kidney exchange programme, 
helping biologically incompatible 
donor–recipient pairs to find suitable 
kidneys, thereby saving the health-
insurance system additional funds. 
However, such savings are not deemed 
enough for Global Kidney Exchange 
proponents, who instead suggest 
that we forget Alyson’s child and look 
for another pair in low-income and 
middle-income countries (LMICs).
In exchange for a kidney from an 
LMIC pair, the recipient from that pair 
would be offered a transplantation in 
an HIC and a US$50 000 escrow fund 
to cover limited-time immunosuppres-
sion and follow-up. The LMIC kidney 
recipient would then be left to rely 
on their own resources. Should the 
LMIC donor have permanent disability 
or kidney failure, they would be in 
a similarly hopeless situation to the 
recipient. However, in the HIC all 
parties would be substantially better 
off, because multiple pairs would have 
received kidneys, the insurance scheme 
would have maximised savings, and 
the transplantation centres involved 
would have received their share of 
money for their services. Everyone 
would have gained, except for Alyson’s 
child.
Arguably, there is exploitation here 
because the system in the HIC has 
taken unfair advantage of an unjust 
situation in which it can choose how 
to save oney, while Alyson’s child is not 
even considered as a transplantation 
candidate, and the pair in the LMIC 
is offered the choice of taking what 
is offered or receiving nothing at all. 
This situation is a concern expressed 
by the Council of Europe’s Committee 
on Organ Transplantation4 and the 
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The Global Kidney 
Exchange programme
We read the Health Policy about the 
Global Kidney Exchange programme 
by Francesca Minerva and colleagues1 
with interest.
Suppose that Alyson, who grows 
crops on her family’s small plot in 
Ohio, USA, cannot afford the kidney 
transplant that will save her child’s life. 
Any public or private health-insurance 
Francesca Minerva and colleagues1 
recently presented an ethical solution 
to kidney failure, in response to the 
low numbers of transplantations in 
high-income countries (HICs) and 
low-income and middle-income 
countries (LMICs). It is the Global 
Kidney Exchange (GKE) programme, 
which matches donor–recipient pairs 
across HICs and LMICs.
It is worth noting two main 
ethical problems with GKE. The main 
problem is that GKE cannot properly 
be considered to be a donation, 
because even though at the level of the 
individual each person does donate, 
at the level of the group there is a true 
commodity exchange, like trade in 
any other market. To prove that GKE 
does not follow market rules, it is not 
sufficient to argue that the “donors 
are not selling because no money is 
paid for the kidney”, as did Minerva 
